Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically proven small cell lung cancer * Patients currently receiving 4-6 cycles of chemotherapy regimen with VP-16 and a platinum-based drug as first-line therapy in the absence of disease progression * Age between 18-75 * Performance status ≤2 * No uncontrolled metabolic disease, infection, and neurological disorders * No congestive heart failure, severe arrhythmia, and coronal atherosclerosis heart disease * Life expectancy more than three months. * Without contraindication of immunotherapy with autologous cytokine-induced killer cells * No other malignancies * Signed study-specific consent form prior to study entry Exclusion Criteria: * Patients receiving other anti-tumor therapy (like thermotherapy) * Pregnant or lactating women * Allergy or unacceptable toxicity of immunotherapy with autologous cytokine-induced killer cells * Uncontrolled mental disorder * Patient having acute hepatitis virus infection, active tuberculosis, or other acute infectious diseases